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The EPIRARE project[1] aims to build consensus and
synergies for the development of an EU platform for rare
disease registries and to address relevant regulatory, ethi-
cal and technical issues associated with the registration
of rare disease patients. To this aim, a survey was carried
out among existing rare disease registries and databases
to get information on their objectives, needs, governance
mechanisms, sustainability, and measures for the compli-
ance with regulatory and ethical requirements and for
quality assurance, as well as expectations from and opi-
nions on a registry platform. Responses were received
from 255 registries, of which 220 active registries were
selected based on the completeness of the response.
Among responding registries, 18, 61, 17 and 3% were
international, national, regional or local. The fraction of
registries population based, hospital based and following
case series or cohorts was, respectively 56, 23 and 20%.
Epidemiological and clinical researches were the most
declared scopes (respectively 71, 61% in a multiple
answer question) and characterized two clearly different
clusters of registries. Treatment efficacy and safety was
the scope indicated by 45% registries. A wide heterogene-
ity is found regarding the disease coding system used,
with 62% using their own or no code. Twenty-seven per-
cent registries are established by law or to comply with
regulatory requirements, while 73% as part of research
projects or as an autonomous decision of clinicians or
patients. Half of the registries shares data with other
registries and 33% with centres of expertise, while 30%
do not exchange with neither of them or with bio banks.
Registries were established with no initial funding (21%)
or with funding by public authorities (37%), industries
and foundations (21%), research institutes and hospitals
(25%), patients associations (16%) and the European
Commission (15%). After the initial phase, more regis-
tries (25%) are run without specific funding; frequency of
funding sources remains stable but for the European
Commission, which decreases to 6%. Different proce-
dures are applied for quality assessment, but each of
them is applied by 46-58% registries. A main governing
body is not present in 34% registries and 48% registries
have no policy to ensure long-term sustainability. Main
needs expressed are financial support, improved commu-
nication strategies and more extended geographical cov-
erage, data sources and registry networking. The vast
majority of respondents (80%) is favourable to a platform
for registries and 60% doubts that new legislation can
facilitate registration. Popularly expected platform ser-
vices are technological tools, specific expert advice and
resources.
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